What can we help you find? - Merck
2 days ago · The safety and efficacy of the combination of islatravir and lenacapavir have not been established. Lenacapavir is being studied in multiple ongoing early and late-stage development programs and has the potential to offer a diverse set of person-centric options for treatment that could uniquely fit into the lives of people with HIV.
Gilead, Merck announce from Phase 2 islatravir/lenacapavir …
1 day ago · The proportion of individuals with HIV-1 RNA less than50 c/mL at Week 48 by FDA snapshot algorithm, showed that participants who switched to treatment with once-weekly islatravir and lenacapavir ...
Gilead and Merck Announce Phase 2 Data Showing a ... - Business …
2 days ago · Islatravir in combination with lenacapavir is investigational and not approved anywhere globally. The safety and efficacy of the combination of islatravir and lenacapavir have not been established.
Islatravir plus lenacapavir could be the first once-weekly
Mar 6, 2024 · The FDA lifted the hold, and Merck launched a new set of studies testing a lower daily dose of islatravir in combination with doravirine and restarted the trial with Gilead using a lower weekly dose of islatravir with lenacapavir. Now, the …
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of …
Sep 20, 2022 · The Phase 2 clinical trial (NCT05052996) evaluating an investigational oral once-weekly combination treatment regimen of islatravir and Gilead’s lenacapavir in adults with HIV-1 infection who are virologically suppressed will resume under an amended protocol with a lower dose of islatravir.
Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir …
1 day ago · The proportion of individuals with HIV-1 RNA less than 50 c/mL at Week 48 by FDA snapshot algorithm (a secondary endpoint), showed that participants who switched to treatment with once-weekly ...
What can we help you find? - Merck
Mar 6, 2024 · Two participants discontinued islatravir and lenacapavir due to adverse events unrelated to the drug. In addition, no differences were seen between treatment groups for changes in CD4+ T cell counts or absolute lymphocyte counts.
Full Efficacy and Safety Results for Gilead Investigational Twice ...
Jul 24, 2024 · Detailed data from the trial’s interim analysis announced in June showed that lenacapavir, the company’s twice-yearly injectable HIV-1 capsid inhibitor, demonstrated zero infections, 100% efficacy and superiority to background HIV incidence for the investigational use of HIV prevention in cisgender women (women assigned female at birth).
Efficacy and safety of the novel capsid inhibitor lenacapavir to …
Jul 11, 2023 · Oral lenacapavir is being investigated in an all-oral daily combination regimen with bictegravir (NCT05502341) and in an all-oral, once-weekly dual combination regimen with islatravir (NCT05052996) in people living with HIV who are virologically suppressed and have either had virological failure or not, respectively. Efforts are in progress to ...
Combination Investigational HIV Therapy Shows Viral Suppression …
1 day ago · 1.Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48. Gilead press release. October 19, 2024. Accessed October 20, 2024. 2.Colson A, et al. 577 - Week …
- Some results have been removed